Conditions: Psoriasis
Keywords: CP-690,550 Etanercept Moderate Severe Chronic Plaque Psoriasis Efficacy Safety Tofacitinib Xeljanz OPT Compare OPT head-to-head non-inferiority Psoriasis vulgaris short-term Itch Pruritus Plaque psoriasis DLQI
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1101
Healthy volunteers: no

Brief summary:
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: CP 690,550 5 mg intervention 2: CP 690,550 10 mg intervention 3: Etanercept 50 mg intervention 4: Placebo
Intervention descriptions: intervention 1: CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks intervention 2: CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks intervention 3: Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks intervention 4: Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.

Protocol document: